Editorial & Medical Review Policy
HIV prevention is a decision people make about their own health, so our information has to be accurate, current and honest. This page explains exactly how we research, write, review and update everything on Prepmedication.com — and how we stay independent.
Our commitment
How we build content — our evidence hierarchy
When sources disagree or evidence is still emerging, we prefer the higher tier and say so plainly.
- National & international clinical guidelines — U.S. CDC, WHO, USPSTF, and equivalents such as BHIVA/BASHH (UK) and ASHM (Australia).
- Regulatory labelling — approved product information from the FDA (and EMA/TGA), which defines who each medicine is licensed for.
- Peer-reviewed trials & systematic reviews — the landmark evidence base (e.g. iPrEx, IPERGAY, HPTN 083/084, PURPOSE-1/2, and the DoxyPEP studies).
- Expert clinical consensus — used only where formal guidance has not yet caught up, and always labelled as such.
Our medical review process
Nothing clinical is published on a writer’s word alone. Each page moves through a defined workflow:
What “medically reviewed” means here: a clinically-experienced reviewer has checked the page against the current guidelines cited at the bottom of that page. It does not mean the content has been personalised to you — only a clinician who examines you can do that.
Who reviews our content
Our content is produced by health writers and reviewed by our Medical Review Team — clinicians and health professionals with experience in HIV prevention, sexual health and pharmacology. We describe the team by the roles that shape every page; individual reviewer bylines are added to articles as reviewers are assigned.
Editorial independence & funding
Accuracy, updates & corrections
Medicine changes — new approvals (like twice-yearly lenacapavir in 2025), new dosing options and new guidance appear regularly. When they do, we update the affected pages and refresh their review date. If you believe something here is inaccurate or out of date, please tell us: we take corrections seriously and fix confirmed errors promptly.
What this site is — and isn’t
Primary sources we rely on
- U.S. CDC — PrEP for the Prevention of HIV Infection: Clinical Practice Guideline (2021); Guidelines for Doxycycline Post-Exposure Prophylaxis (2024); nPEP guidelines (2016).
- WHO — Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring (2021, with 2022–2024 updates on event-driven and long-acting PrEP and the dapivirine ring).
- USPSTF — Prophylaxis for the Prevention of HIV Infection: Recommendation Statement (2023).
- Regulators — U.S. FDA labelling for Truvada, Descovy, Apretude (2021) and Yeztugo / lenacapavir (2025); EMA/TGA equivalents.
- Key trials — iPrEx, IPERGAY, HPTN 083/084, PURPOSE-1 & 2, and the DoxyPEP studies.
© 2026 PrEPMedication.com
Symptom Map · PrEP Options · Compare · Drug Checker · PEP
Truvada · Descovy · Apretude · Editorial policy · Privacy